[203Pb]Pb-VMT-α-NET 0期成像试验:为[212Pb]Pb-VMT-α-NET治疗难治/复发转移性神经内分泌肿瘤提供剂量学与治疗计划
该0期成像试验于2023年1月至12月纳入10例SSTR2阳性神经内分泌肿瘤患者,静脉注射约185 MBq [203Pb]Pb-VMT-α-NET后行SPECT/CT及血液采样。162个SSTR2 PET/CT病灶中仅97个被检出,>1 cm病灶灵敏度94%,≤1 cm或不可测量病灶为35%;基于203Pb成像估算212Pb药物器官和肿瘤剂量,[203Pb]Pb-VMT-α-NET有效剂量为0.038 mSv/MBq。
要点
- [203Pb]Pb-VMT-α-NET SPECT/CT对>1 cm NET病灶灵敏度94%,≤1 cm或不可测量病灶仅35%。
- 病灶最高信噪比出现在给药后4 h。
- 基于203Pb成像可估算212Pb治疗药物的器官和肿瘤吸收剂量。
核心结论
- [203Pb]Pb-VMT-α-NET似乎是安全有效的SPECT/CT示踪剂,可用于>1 cm NET成像及正常器官和肿瘤辐射剂量学。
- 化学匹配的203/212Pb诊疗对有望支持剂量学驱动的个体化治疗模式。
研究设计与样本
- 0期成像试验于2023年1月至12月开展,纳入10例SSTR2阳性神经内分泌肿瘤患者。
- 患者静脉输注约185 MBq [203Pb]Pb-VMT-α-NET,于1、4、24、48 h行SPECT/CT和血液采样。
- 以基线SSTR2 PET/CT为参照进行逐病灶比较,部分病灶分析信噪比以确定最佳诊断成像时间点。
- 基于203Pb成像和假设局部α/β能量沉积于肿瘤和正常器官,推导[212Pb]Pb-VMT-α-NET患者个体化剂量学。
- 使用基于ICRP发表参数的全身体药代动力学模型考虑子体离子再定位效应。
主要发现
- SSTR2 PET/CT识别的162个病灶中,仅97个在[203Pb]Pb-VMT-α-NET SPECT/CT上检出。
- 病灶最高信噪比出现在[203Pb]Pb-VMT-α-NET给药后4 h。
- >1 cm病灶灵敏度为94%,≤1 cm或不可测量病灶灵敏度为35%。
- [203Pb]Pb-VMT-α-NET给药相关有效剂量为0.038 mSv/MBq(1.40 mSv/mCi)。
- 基于[203Pb]Pb-VMT-α-NET SPECT/CT估算的[212Pb]Pb-VMT-α-NET剂量(均值±SD,未校正相对生物效应):肾脏15±4.7 mGy/MBq,脾8.4±4.1 mGy/MBq,肝2.5±0.8 mGy/MBq,血0.324±0.108 mGy/MBq,全身0.270±0.081 mGy/MBq,肿瘤29.6±25.8 mGy/MBq。
关键数值与推荐
- >1 cm病灶灵敏度94%,≤1 cm或不可测量病灶灵敏度35%。
- 最佳诊断成像时间点为给药后4 h(基于病灶信噪比)。
- [203Pb]Pb-VMT-α-NET有效剂量0.038 mSv/MBq(1.40 mSv/mCi)。
- [212Pb]Pb-VMT-α-NET估算剂量(均值±SD,未校正RBE):肾15±4.7、脾8.4±4.1、肝2.5±0.8、血0.324±0.108、全身0.270±0.081、肿瘤29.6±25.8 mGy/MBq。
- 212Pb肾脏吸收剂量预测总体标准不确定度(k=1)为15.3%。
临床怎么用
- 可利用[203Pb]Pb-VMT-α-NET SPECT/CT对>1 cm SSTR2阳性NET病灶进行成像评估。
- 给药后4 h可能是[203Pb]Pb-VMT-α-NET SPECT/CT的最佳诊断成像时间点。
- 基于203Pb成像可估算212Pb治疗药物的器官和肿瘤吸收剂量,为剂量学驱动个体化治疗提供依据。
局限性
- 样本量仅10例,为0期成像试验。
- [203Pb]Pb-VMT-α-NET SPECT/CT对≤1 cm或不可测量病灶灵敏度仅35%,检出有限。
- 212Pb剂量学基于203Pb成像和局部能量沉积假设推导,未校正相对生物效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) using α-particle emitters has potential to provide improved patient outcomes over those achieved with β-particle PRRT. A promising candidate radiopharmaceutical pair, PSC-PEG2-TOC (VMT-α-NET) conjugated to 203Pb for SPECT/CT imaging or 212Pb for α-PRRT, is currently in early-phase clinical trials for patients with neuroendocrine tumors (NETs). Here, we present the imaging and dosimetry characteristics of this theranostic approach. Methods: A phase 0 imaging trial of [203Pb]Pb-VMT-α-NET was conducted between January and December of 2023. Ten participants with somatostatin receptor type 2 (SSTR2)-positive NETs underwent SPECT/CT and blood sampling at 1, 4, 24, and 48 h after intravenous infusion of approximately 185 MBq of [203Pb]Pb-VMT-α-NET. The diagnostic performance of [203Pb]Pb-VMT-α-NET was evaluated through lesion-by-lesion comparison against baseline SSTR2 PET/CT. A subset of lesions was further analyzed for signal-to-noise ratio to determine the optimal diagnostic imaging time point after [203Pb]Pb-VMT-α-NET administration. Patient-specific dosimetry of [212Pb]Pb-VMT-α-NET was derived from 203Pb imaging and performed assuming local α- and β-particle energy deposition in tumors and normal organs. Effects of daughter ion relocation were considered using a whole-body pharmacokinetic model on the basis of parameters published by the International Commission on Radiological Protection. Results: Of the 162 total lesions identified on SSTR2 PET/CT scans, only 97 were detected on [203Pb]Pb-VMT-α-NET SPECT/CT. The highest signal-to-noise ratio for lesions occurred 4 h after [203Pb]Pb-VMT-α-NET administration. Sensitivity was 94% for lesions larger than 1 cm versus 35% for lesions no larger than 1 cm or nonmeasurable lesions. The effective dose associated with [203Pb]Pb-VMT-α-NET administration was 0.038 mSv/MBq (1.40 mSv/mCi). Estimated dosimetry for [212Pb]Pb-VMT-α-NET (mean ± SD, not adjusted for relative biologic effectiveness) based on [203Pb]Pb-VMT-α-NET SPECT/CT was 15 ± 4.7 mGy/MBq for the kidneys, 8.4 ± 4.1 mGy/MBq for the spleen, 2.5 ± 0.8 mGy/MBq for the liver, 0.324 ± 0.108 mGy/MBq for the blood, 0.270 ± 0.081 mGy/MBq for the whole body, and 29.6 ± 25.8 mGy/MBq for tumors. Renal absorbed dose projections for 212Pb were estimated to carry an overall standard uncertainty (k = 1) of 15.3%. Conclusion: [203Pb]Pb-VMT-α-NET appears to be a safe and effective SPECT/CT tracer for imaging NETs larger than 1 cm and for normal organ and tumor radiation dosimetry. The chemically matched 203/212Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm.
引用
- Graves SA, Bushnell DL, Schultz MK, et al. A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET. J Nucl Med. 2026. PMID: 41644295. doi:10.2967/jnumed.125.270083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。